Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Down 0.1%

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) were down 0.1% during trading on Tuesday . The stock traded as low as $7.13 and last traded at $7.22. Approximately 356,959 shares changed hands during trading, a decline of 17% from the average daily volume of 431,707 shares. The stock had previously closed at $7.23.

Analyst Ratings Changes

ZVRA has been the topic of several research analyst reports. HC Wainwright increased their target price on shares of Zevra Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $20.33.

Zevra Therapeutics Stock Up 2.7 %

The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The stock’s 50 day simple moving average is $6.67 and its 200 day simple moving average is $5.66. The firm has a market cap of $317.66 million, a P/E ratio of -5.56 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The business had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. Research analysts anticipate that Zevra Therapeutics, Inc. will post -1.58 EPS for the current year.

Insider Transactions at Zevra Therapeutics

In related news, Director Thomas Anderson bought 10,000 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were bought at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the acquisition, the director now directly owns 20,000 shares of the company’s stock, valued at $136,200. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders purchased a total of 22,000 shares of company stock valued at $140,340 over the last ninety days. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new stake in Zevra Therapeutics in the 1st quarter worth about $64,000. The Manufacturers Life Insurance Company increased its position in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after acquiring an additional 2,452 shares during the last quarter. IFG Advisors LLC lifted its holdings in Zevra Therapeutics by 45.0% during the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after acquiring an additional 5,800 shares during the period. Focus Financial Network Inc. ADV purchased a new position in Zevra Therapeutics in the fourth quarter worth $141,000. Finally, Virtu Financial LLC bought a new position in Zevra Therapeutics in the 4th quarter valued at $177,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.